期刊
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
卷 32, 期 2, 页码 186-191出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.beha.2019.05.003
关键词
AML; Measurable residual disease (MRD); Allogeneic stem cell transplantation; Multicolor flowcytometry; qPCR; Leukemic stem cells
类别
Measurable residual disease (MRD) can be assessed either by flow cytometry or molecular techniques. It has been proven to be highly prognostic in quite a number of prospective clinical studies. The recently published ELN MRD recommendations aim harmonize the approaches to MRD assessment in order to improve its overall quality. The predictive value leading to the usage as a surrogate endpoint for survival which would be instrumental for faster drug approvals has still to be proven. Nevertheless, many AML centers use MRD status to inform treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据